CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63).

MLA

Hsi, Eric D., et al. “CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63).” Blood, vol. 112, no. 11, Nov. 2008, p. 1779. EBSCOhost, https://doi.org/10.1182/blood.V112.11.1779.1779.

APA

Hsi, E. D., Steinle, R., Balasa, B., Rice, A., Ko, Y.-H., & Afar, D. E. H. (2008). CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63). Blood, 112(11), 1779. https://doi.org/10.1182/blood.V112.11.1779.1779

Chicago

Hsi, Eric D, Roxanne Steinle, Balaji Balasa, Audie Rice, Young-Hyeh Ko, and Daniel E.H. Afar. 2008. “CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63).” Blood 112 (11): 1779. doi:10.1182/blood.V112.11.1779.1779.